The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
|Articles|March 25, 2020
Contagion Live News Network: Coronavirus Updates for March 25, 2020
Author(s)Michaela Fleming
Stay on top of coronavirus news from March 24, 2020.
Advertisement
Welcome to the Contagion Live News Network. I’m Michaela Fleming and this is the COVID-19 update for Wednesday March 25th, 2020.
As of this afternoon there are more than 454,000 cases of the novel coronavirus worldwide. The cases in Italy are likely to eclipse the number in China in the near future. Italy has recorded over 75,000 cases and 5700 deaths.
Cases are surging in the US where more than 60,000 cases have been confirmed. New York remains the epicenter of the US outbreak with over 30,000 cases.
Early this morning it was announced that US lawmakers have come to agreement on a $2 trillion stimulus package.
Yesterday, the
Be sure to check out new articles on Contagion, including a writeup on
Tonight at 6pm Contagion is hosting a
For more information on COVID-19, visit ContagionLive.com. To track the spread of coronavirus in the United States and abroad, be sure to use the
For the Contagion Live News Network, I’m Michaela Fleming. Thanks for tuning in.
Advertisement
Related to this article
Investigational agent Zelicapavir cut time to complete RSV symptom resolution by up to a week and lowered hospitalization in high-risk adults.
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Oral zelicapavir cut time to complete RSV symptom resolution by up to 1 week in high-risk adults, but it did not meet its primary end point in a phase 2 trial.
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.
An APP-driven complex outpatient antimicrobial therapy (COpAT) program for patients with bone and joint infections cut mean time to post-discharge follow-up from 20.1 to 9.7 days but did not significantly reduce 30-day readmissions or emergency department visits.
Advertisement
Advertisement
Trending on Contagion Live
1
A Closer Look at IDSA/ESCMID 2026 Consensus Statements 6 and 7 on Staphylococcus aureus Bacteremia
2
Measles Update: October 30, 2026
3
Thinking Outside the IV: Implementation of a COpAT Program for Patients With Bone and Joint Infections
4
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
5